This is a multi-center, open-labeled study to examine the non-inferiority of ASP1585 to sevelamer hydrochloride in chronic kidney disease patients with hyperphosphatemia on hemodialysis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
110
oral
oral
Unnamed facility
Chūbu, Japan
Unnamed facility
Kantou, Japan
Unnamed facility
Kyusyu, Japan
Serum phosphorus level at the end of treatment
Time frame: After 12-week or at the treatment discontinuation
Change in serum phosphorus level
Time frame: After 12-week or at the end of treatment
Time-course changes in serum phosphorus levels
Time frame: During Treatment
Changes in serum Ca x P
Time frame: During treatment
Changes in intact PTH levels
Time frame: During Treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.